PETALING JAYA: DKSH Business Unit Healthcare, a partner for companies seeking to grow their healthcare business in Asia and beyond, has entered into a partnership with Pfizer (Malaysia) Sdn Bhd, a subsidiary of the global pharmaceutical company Pfizer Inc, to provide comprehensive distribution, sales, and marketing services for Pfizer’s anti-infectives portfolio throughout Malaysia.
Pfizer’s anti-infectives portfolio comprises a strong mix of established therapies that play a vital role in treating moderate to severe infections, alongside newer, clinically robust antimicrobial treatments.
Under this collaboration, DKSH will manage end-to-end commercial operations, including warehousing, nationwide distribution, and integrated sales and marketing support across all healthcare channels.
By combining Pfizer’s scientific innovation with DKSH’s extensive commercial infrastructure and deep market expertise, the collaboration aims to significantly broaden access to essential antimicrobial therapies across the market.
Pfizer (Malaysia) SdnBhd cluster head (Malaysia, Indonesia, Singapore, Philippines), Deborah Seifert said they apply science and their global resources to bring therapies to people that extend and significantly improve their lives.
DKSH vice-president, healthcare and head, country leadership, Sandeep Tewari said:
“This partnership reflects our shared commit
ment to improving patient outcomes by ensuring timely access to innovative and essential antimicrobial therapies. By combining Pfizer’s strong scientific leadership with DKSH’s proven commercial capabilities and extensive distribution network, we aim to deliver greater value to healthcare providers and patients nationwide, providing better healthcare for all.”
Together, DKSH Malaysia and Pfizer are committed to strengthening infection management in Malaysia and advancing patient care through timely access to essential therapies.
